

# Helping you navigate the evolving **monoclonal antibody (mAb) landscape**

Decades of antibody production from a leading CDMO powered by Pfizer and backed by world class manufacturing facilities.



What does it take to effectively support monoclonal antibody (mAb) production now and in the future?



## Exceptional capabilities and expertise

Developers and manufacturers will face many challenges throughout antibody therapeutic production, from optimizing culture conditions to improving yield and ensuring manufacturing scalability. Overcoming these hurdles relies on a diverse suite of services and a high level of know-how.




## Proactively preparing for innovative modalities

Looking ahead and tracking promising research in the space will enable developers and manufacturers to be ready for when the next game-changer inevitably emerges.



## Early adoption of new technologies

To help meet the continuously growing demand, developers and manufacturers must embrace the latest technological advancements to keep pace – single-use technologies are a prime example.



# Specialized mAb facilities

The bio-logical choice for your mAb manufacturing with a global network of support



Clinical manufacturing to commercial capability — covering large-scale supply of drug substance and product



Drug product capabilities up to 20 liter batches (Sanford, USA) or larger at one of our many global sites



Industry leading yield and productivity ratios, with cell culture scale up to 2K liters



Extensive testing experience, bioassays and protein-specific techniques



Single-use facilities with the ability to switch to stainless steel in solutions prep and centrifugation



Cold-chain handling and warehousing



Cell culture medium development and optimization



A significant number of Good Manufacturing Practice (GMP) batches and proven quality control



Discover how we can help **accelerate your mAbs journey to market** with reliability and quality

[Click here to learn more](#)